Valneva (VALN.US) said on May 16 that the European Commission (EC) intended to terminate its advance purchase Agreement (APA) for the company's inactivated Covid-19 whole virus vaccine VLA2001. It is reported that in November 2021, Valneva signed a pre-purchase agreement with the European Commission to provide up to 60 million doses of vaccine within two years, including 24.3 million doses by 2022.
Valneva said that under the terms of APA, the company has 30 days from May 13, 2022 to obtain listing permission or propose an acceptable remedial plan. The company added that it had submitted a response to EMA's latest request on May 2.
Valneva said that under the terms of APA, the company has 30 days from May 13, 2022 to obtain listing permission or propose an acceptable remedial plan. The company added that it had submitted a response to EMA's latest request on May 2.